Isavuconazole

• CAT Number: I002804
• CAS Number: 241479-67-4
• Molecular Formula: C22H17F2N5OS
• Molecular Weight: 437.47
• Purity: ≥95%
• Target: Antifungal
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: 4-[2-[(2R,3R)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile
• InChI: InChI=1S/C22H17F2N5OS/c1-14(21-28-20(10-31-21)16-4-2-15(9-25)3-5-16)22(30,11-29-13-26-12-27-29)18-8-17(23)6-7-19(18)24/h2-8,10,12-14,30H,11H2,1H3/t14-,22+/m0/s1
• InChIKey: DDFOUSQFMYRUQK-RCDICMHDSA-N
• SMILES: N#CC1=CC=C(C2=CSC([C@@H]([C@@](O)(C3=CC(F)=CC=C3F)CN4N=CN=C4)C)=N2)C=C1

Isavuconazole (Cat.No:I002804) is a broad-spectrum antifungal medication used to treat invasive fungal infections. It belongs to the triazole class of antifungal drugs and works by inhibiting the synthesis of ergosterol, a key component of fungal cell membranes. Isavuconazole is effective against a range of fungal species, including Aspergillus and Candida, and is available in both oral and intravenous formulations.

Reference

1:Implementation of Isavuconazole in a Fluorescence-Based High-Performance Liquid Chromatography Kit Allowing Simultaneous Detection of All Four Currently Licensed Mold-Active Triazoles. Jørgensen R, Andersen SR, Astvad KMT, Arendrup MC.mSphere. 2017 May 10;2(3). pii: e00098-17. doi: 10.1128/mSphere.00098-17. eCollection 2017 May-Jun. PMID: 28497121 Free PMC Article2:Successful Treatment of Allergic Bronchopulmonary Aspergillosis With Isavuconazole: Case Report and Review of the Literature. Jacobs SE, Saez-Lacy D, Wynkoop W, Walsh TJ.Open Forum Infect Dis. 2017 May 5;4(2):ofx040. doi: 10.1093/ofid/ofx040. eCollection 2017 Spring. PMID: 28491888 Free PMC Article3:Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response. Kovanda LL, Kolamunnage-Dona R, Neely M, Maertens J, Lee M, Hope WW.Clin Infect Dis. 2017 Jun 1;64(11):1557-1563. doi: 10.1093/cid/cix198. PMID: 28472247 4:Use of isavuconazole in a patient with voriconazole-induced QTc prolongation. Trang TP, Hanretty AM, Langelier C, Yang K.Transpl Infect Dis. 2017 Apr 23. doi: 10.1111/tid.12712. [Epub ahead of print] PMID: 28434195 5:Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates. Astvad KM, Hare RK, Arendrup MC.Clin Microbiol Infect. 2017 Mar 31. pii: S1198-743X(17)30192-1. doi: 10.1016/j.cmi.2017.03.023. [Epub ahead of print] PMID: 28373148 Free Article6:Isavuconazole: is there a need for a new antifungal? Cornely OA.J Antimicrob Chemother. 2017 Mar 1;72(suppl_1):i2-i4. doi: 10.1093/jac/dkx027. No abstract available. PMID: 28355461 7:The Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole. Kovanda LL, Marty FM, Maertens J, Desai AV, Lademacher C, Engelhardt M, Lu Q, Hope WW.Antimicrob Agents Chemother. 2017 Mar 13. pii: AAC.00101-17. doi: 10.1128/AAC.00101-17. [Epub ahead of print] PMID: 28289034 Free Article8:Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics. Townsend RW, Akhtar S, Alcorn H, Berg JK, Kowalski DL, Mujais S, Desai AV.Eur J Clin Pharmacol. 2017 Jun;73(6):669-678. doi: 10.1007/s00228-017-2213-7. Epub 2017 Mar 7. PMID: 28271239 9:Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis. Gebremariam T, Alkhazraji S, Baldin C, Kovanda L, Wiederhold NP, Ibrahim AS.Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02589-16. doi: 10.1128/AAC.02589-16. Print 2017 May. PMID: 28264840 10:In vitro combination therapy with isavuconazole against Candida spp. Katragkou A, McCarthy M, Meletiadis J, Hussain K, Moradi PW, Strauss GE, Myint KL, Zaw MH, Kovanda LL, Petraitiene R, Roilides E, Walsh TJ, Petraitis V.Med Mycol. 2017 Feb 16. doi: 10.1093/mmy/myx006. [Epub ahead of print] PMID: 28204571